louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01302912: Lymphoma in the Orbit
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma
Keywords: ocular adnexal lymphomas
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2011-02-24
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patient, who underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at the University Hospital Zurich, Division of Ophthalmology

Brief summary: Imaging techniques have considerably improved over the last decades and ocular adnexal lymphomas (OALs) nowadays can be detected. As major advances in immunophenotyping and molecular diagnostics in histology have been achieved offering an accurate diagnosis, the investigators would like to introduce that surgical biopsy of an orbital lymphoma becomes crucial for the possibility of a correct diagnosis and proper treatment. As radiotherapy accomplished great preciseness as well and OALs respond excellently to radiation, this therapy should be the treatment of choice in local defined lymphomas instead of blind treatment with steroids. Radiation results in great local control rates of 85% to 100%

* Trial with surgical intervention


Eligibility criteria: Inclusion criteria: - both genders

* \>17 years of age
* underwent biopsy of an ocular adnexal lymphoma between 01/2006 and 12/2010 at the University Hospital Zurich, Division of Ophthalmology
* diagnosis histologically proven

Exclusion criteria:

* less than 18 years of age
* patient underwent no MRI before surgery (biopsy)

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Ophthalmic Clinic
state: ZH
Study officials:
affiliation: University Hospital Zurich, Ophtalmic Clinic
name: Karla Chaloupka, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01533012: Initial Positioning of Left Sided Double Lumen Endobronchial Tubes Using Peak Inspiratory Pressures Difference Between Two Lungs
Official title: Initial Positioning of Left Sided Double Lumen Endobronchial Tubes Using Peak Inspiratory Pressures Difference Between Two Lungs
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Thoracic Surgery
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2012-02-15
Enrollment: 104
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate a performance of initial positioning of left sided double lumen endobronchial tubes using peak inspiratory pressures difference between two lungs.

Detailed description: If both lungs have relatively equal volumes and the double lumen tube is in a satisfactory position, peak inspiratory pressure between two lungs is similar or equal when each lumen is sequentially clamped while ventilating each lung with the same tidal volume. We are going to investigate a performance of this method by fiberoptic bronchoscopy view and depth of double lumen tube, and compare with an conventional auscultation method.

Eligibility criteria: Inclusion Criteria:

* ASA physical status class I, II
* Use of double lumen tube
* Normal preoperative pulmonary function study

Exclusion Criteria:

* COPD
* Restrictive lung disease
* CAOD
* Unstable hemodynamic status
* Peak inspiratory pressure \> 30 mm Hg (Two lung ventilation)

Primary outcomes:
measure: Fiberoptic bronchoscopy view
timeFrame: within 5 min after intubation
Secondary outcomes:
measure: depth of double lumen tube
timeFrame: within 5 min after checking fiberopitics
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Department of Anesthesiology and Pain Medicine , Anesthesia and Pain Research Institute, Yonsei University College of Medicine
Study officials:
References:
citation: Kim SH, Choi YS, Shin S, Cho JS, Nam DJ, Oh YJ. Positioning of double-lumen tubes based on the minimum peak inspiratory pressure difference between the right and left lungs in short patients: a prospective observational study. Eur J Anaesthesiol. 2014 Mar;31(3):137-42. doi: 10.1097/EJA.0b013e328364c3a7.
Clinical trial NCT05618912: Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment
Official title: Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Scar
Skin Scarring
Skin Cancer
Wound Heal
Wound of Skin
Surgical Wound
Patient Satisfaction
Patient Preference
Surgical Incision
Keywords: scar
dermatologic surgery
wound healing
wound of skin
skin cancer
surgical incision
patient satisfaction
patient preference
cosmetic outcome
scar appearance
Lead sponsor: Indiana University
Sponsor class: OTHER
First posted: 2022-11-16
Enrollment: 146
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Each patient will have the surgical scar treated with either type of intervention
Primary purpose: TREATMENT

Brief summary: Patients will be randomized either to receive standard daily dressing or hydrocolloid dressing using a randomization generator. After closing the wound with the sutures,the scar will be covered by a hydrocolloid dressing, which will be left in place for 7 days(Experimental) or the standard dressing (Control) that will be covered with petrolatum jelly and bandaging during this time period, which has to be re-applied daily. Patients and dermatologic surgeons will then complete surveys 7 days, 30 days, and 90 days after surgery to evaluate the cosmetic appearance of these scars.


Eligibility criteria: Inclusion Criteria:

1. Adult \> 18 years of age
2. Linear scars
3. Patients underwent conventional excision or Mohs micrographic surgery for primary cutaneous cancer or other cutaneous condition that required surgical intervention

Exclusion Criteria:

1. Scar localization on acral or hair bearing sites
2. Patients unable to converse in English
3. Patients requiring flap or graft for closure of wound
4. History of allergy to adhesives
5. Patient using topical chemotherapy agents on the surgical site or planning to start it within 3 months after surgery
6. Use of hydrocolloid dressings for post-operative wound care in the past

Primary outcomes:
measure: Cosmetic Outcome
timeFrame: 7 days
measure: Cosmetic Outcome
timeFrame: 30 days
measure: Cosmetic Outcome
timeFrame: 90 days
Secondary outcomes:
measure: Number of Participants With Complications
timeFrame: 7 days, 30 days, 90 days
Other outcomes:
Locations:
city: Carmel
country: United States
facility: IU Health Physicians Dermatology Meridian Crossing
state: Indiana
Study officials:
References:
citation: Holmes SP, Rivera S, Hooper PB, Slaven JE, Que SKT. Hydrocolloid dressing versus conventional wound care after dermatologic surgery. JAAD Int. 2021 Dec 21;6:37-42. doi: 10.1016/j.jdin.2021.11.002. eCollection 2022 Mar.
Clinical trial NCT01700712: Acid Production in Dental Plaque After Exposure to Probiotic Bacteria
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Caries
Keywords: Caries, probiotic bacteria
Lead sponsor: University of Copenhagen
Sponsor class: OTHER
Collaborators: name: BioGaia AB
name: Calcin foundation, Denmark
First posted: 2012-10-04
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The increasing interest in probiotic lactobacilli in health maintenance has raised the question of potential risks. One possible side effect could be an increased acidogenicity in dental plaque. The aim of this study was to investigate the effect of probiotic lactobacilli on plaque lactic acid (LA) production in vitro and in vivo.

Methods. subjects (n=18) were given lozenges with probiotic lactobacilli (L. reuteri DSM 17938 and ATCC PTA 5289) or placebo for two weeks in a double-blinded, randomized cross-over trial. The concentration of LA in supragingival plaque samples was determined at baseline and after 2 weeks. Salivary counts of mutans streptococci (MS) and lactobacilli were estimated with chair-side methods.


Eligibility criteria: Inclusion Criteria:

* moderate to high counts of salivary mutans streptococci (\>104 CFU) as estimated with the Dentocult SM chair-side test,
* no visible open caries lesions or periodontal disease,

Exclusion Criteria:

* smokers,
* ingestion of probiotic bacteria within the last two months,
* ingestion of antibiotics within the last two months

Primary outcomes:
measure: Acid production in plaque after exposure to probiotic bacteria
timeFrame: 2 weeks
Secondary outcomes:
measure: Acid producton in plaque after in vitro exposure to probiotic bacteria
timeFrame: 1 hour
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: University of Copenhagen
Study officials:
affiliation: University of Copenhagen
name: Mette K Keller, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Keller MK, Twetman S. Acid production in dental plaque after exposure to probiotic bacteria. BMC Oral Health. 2012 Oct 24;12:44. doi: 10.1186/1472-6831-12-44.
Clinical trial NCT05790512: Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
Official title: Association of Oral Helicobacter Pylori Infection With Gastric Helicobacter Pylori Infection
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Helicobacter Pylori
Keywords: Oral Helicobacter Pylori
Helicobacter Pylori Gastric
Lead sponsor: Xijing Hospital of Digestive Diseases
Sponsor class: OTHER
First posted: 2023-03-30
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients are from Xijing Hospital.

Brief summary: The aim of this study was to investigate the association between oral Helicobacter pylori infection and gastric Helicobacter pylori infection. Patients who were tested for gastric Helicobacter pylori were tested for oral Helicobacter pylori at the same time, and were divided into four groups according to the test results to compare the positive rate of oral Helicobacter pylori.


Eligibility criteria: Inclusion Criteria:

1. Age between 18\~70 ,both gender.
2. Initial diagnosis of stomach Helicobacter pylori infection or never had Helicobacter pylori infection.
3. Have not received dental care or systemic periodontal basic treatment in the past 1 year.

Exclusion Criteria:

1. There is serious organ damage and complications (such as cirrhosis, uremia, etc.), severe or unstable cardiopulmonary or endocrine diseases.
2. Ongoing use of antiulcer medications (including PPIs taken within 2 weeks before Helicobacter pylori infection testing), antibiotics, or bismuth complexes (more than 3 times/week before screening).
3. Those with severe oral diseases and malignant tumors of the mouth.
4. Previously had upper gastrointestinal surgery.
5. Refusal to sign informed consent.

Primary outcomes:
measure: Positive rate of oral Helicobacter pylori
timeFrame: 7 months
Secondary outcomes:
Other outcomes:
Locations:
city: Xi'an
country: China
facility: Xijing Hosipital of Digestive Disease
state: Shaanxi
Study officials:
affiliation: Xijing Hosipital of Digestive Disease
name: Yongquan Shi, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00547781: Implantation Failure and PGD
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: IMPLANTATION
Lead sponsor: Instituto Valenciano de Infertilidad, IVI VALENCIA
Sponsor class: OTHER
First posted: 2007-10-23
Enrollment: 250
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this study is to performed a randomized controlled trial to evaluate the usefulness of preimplantation genetic diagnosis (PGD) in patients with repetitive implantation failure. Patients will be prospectively randomized in two groups: standard IVF with blastocyst transfer on day-5 and transfer day-5 after PGD for aneuploidy screening for chromosomes 13, 15, 16, 18, 21, 22, X and Y. The end points of the study are: Cancellation rate; implantation rate and ongoing implantation rate. Inclusion criteria are: patients with ≥2 previous IVF failure without clinical or biochemical pregnancy with transfer of at least 2 good quality embryos per transfer. Exclusion criteria will be uterine abnormalities , abnormal karyotypes, abnormal result in thrombophilia screening and low responder patients (less than 4 expected oocytes).


Eligibility criteria: Inclusion Criteria:

* Patients of any age with ≥2 previous cycles, negative TIG or biochemical pregnancy with fresh transfer of at least 2 embryos in each cycle.

Exclusion Criteria:

* Patients with PGD indication (age, repetitive miscarriage, chromosomal anomalies, etc. )
* Patients with ectopic pregnancies in previous cycles.
* Recipient of oocyte donation.
* Patients in which 4 or less oocytes are to be retrieved.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Valencia
country: Spain
facility: IVI Valencia
Study officials:
affiliation: IVI Valencia
name: Carmen Rubio, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07020481: Spiritual Needs of European Patients With Inflammatory Bowel Disease and Their Caregivers
Official title: Spiritual Needs of Patients With Inflammatory Bowel Disease and Their Caregivers: a European Cross-sectional Nursing Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Inflammatory Bowel Disease (Crohn&#39;s Disease and Ulcerative Colitis)
Lead sponsor: University of Padova
Sponsor class: OTHER
First posted: 2025-06-13
Enrollment: 1000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adolescents and adults of all ages clinically diagnosed with CD, UC, or any other form of IBD (such as indeterminate colitis or IBD unclassified)

Brief summary: A European-wide cross-sectional non-interventional study, initiated by a pilot study in Italy, will be conducted. The first phase of the pilot study is a 6-step translation, adaptation, and validation of the extended version of the Spiritual Needs Questionnaire (SpNQ-EV) and the Interpretation of Illness Questionnaire (IIQ) adopting the methodology \[3\] described in figure 1. To ensure they are both valid and user-friendly, the Thinking Out Loud (TOL) technique (think-aloud method) will pre-test their self-administration and provide fine tuning of the secondary objectives of the study. TOL involves participants verbalizing their thoughts while completing the questionnaires, allowing to capture real-time insights into their understanding, interpretation, and potential challenges with questionnaires' items. The second phase will consist of an anonymous e-survey consisting of the six questionnaires described in table 1 including the translated and validated SPNQ-EV and IIQ developed in phase 1. The European study will employ a multilingual anonymous e-survey developed to ensure accessibility in participants' native languages, eventually preceded by country-based pilot studies. Eligible participants include adolescents and adults with IBD, as well as their caregivers, recruited via nurses and patient associations.


Eligibility criteria: Inclusion Criteria:

* adolescents and adults of all ages clinically diagnosed with CD, UC, or any other form of IBD (such as indeterminate colitis or IBD unclassified).

Primary outcomes:
measure: Spiritual Needs Questionnaire (SpNQ-EV)
timeFrame: Day 1 (From enrollment to the end of data collection (end of questionnaire completion) - same day
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01459081: Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
Official title: Randomised, Double-blind, Placebo-controlled Trial of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in China
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Influenza A Virus Infection
Influenza B Virus Infection
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2011-10-25
Enrollment: 298
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to evaluate the clinical efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections in China.


Eligibility criteria: Inclusion Criteria:

* Who had fever (\>38.0ºC)
* At least two of the following symptoms: chills, headache, myalgia, fatigue, nasal symptoms, sore throat, cough
* Started therapy within 48 hours of onset of influenza-like illness
* Written informed consent

Exclusion Criteria:

* Respiratory diseases, such as asthma or COPD
* Woman with a positive urine pregnancy test
* Woman without contraception during the study
* Allergic to zanamivir, Paracetamol or lactose
* WBC ≥ 10.5×109/L; neutrophil percentage ≥ 80%
* Hepatic function impairment: AST ≥ 2×ULN, ALT ≥ 2×ULN
* Renal function impairment: Cr \> 221μmol/L
* Influenza vaccination in the 12 months prior the beginning of the study
* History of tumor, psychiatric disorders, epilepsy or drug abuse
* Patients receiving corticosteroids, immunosuppressants
* HIV positive

Primary outcomes:
measure: Time to alleviation of clinically important symptoms
timeFrame: up to 21 days
Secondary outcomes:
measure: Symptom score AUC
timeFrame: 6 days
measure: Mean symptom scores
timeFrame: 6 days
measure: The use of relief medication
timeFrame: 6 days
Other outcomes:
Locations:
city: Changsha
country: China
facility: The Third Xiangya Hospital Of Central South University
city: Chengdu
country: China
facility: West China Hospital, Sichuan University
city: Hangzhou
country: China
facility: The First People's Hospital of Hangzhou
city: Huhehaote
country: China
facility: The Affiliated Hospital of Inner Mongolia Medical College
city: Nanchang
country: China
facility: The First Affiliated Hospital of Nanchang University
city: Nanjing
country: China
facility: The First Affiliated Hospital of Nanjing Medical University
city: Qingdao
country: China
facility: Qingdao Municipal Hospital
city: Shanghai
country: China
facility: Shanghai 6th People's Hospital
city: Shanghai
country: China
facility: Shanghai Changzheng Hospital
city: Shenyang
country: China
facility: ShengJing Hospital of China Medical University
city: Xi'an
country: China
facility: Tangdu Hospital Affiliated to the Fourth Military Medical University
city: Yangzhou
country: China
facility: Northern Jiangsu People's Hospital
Study officials:
affiliation: Shanghai Changzheng Hospital
name: Qingyu Xiu, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06712381: Carac & PDT Combination in the Treatment Of Actinic Keratoses
Official title: Carac & PDT Combination in the Treatment Of Actinic Keratoses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Actinic Keratoses
Keywords: Actinic Keratoses
Lead sponsor: Skin Laser & Surgery Specialists
Sponsor class: OTHER
Collaborators: name: Sanofi
First posted: 2024-12-02
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To demonstrate if Carac treatment after PDT treatment of actinic keratoses leads to superior clinical improvement when compared to Carac or PDT treatment alone. This will be done by manual counts and through photography.

Detailed description: Carac has been shown to be highly effective for the treatment of actinic keratoses. Photodynamic Therapy (PDT) has also been shown to be highly effective for the treatment of actinic keratoses. Both treatments are FDA approved. The mechanism of action of each therapy is different. In general a more vigorous, but less cosmetically acceptable appearance is seen after Carac treatment as compared to PDT treatment. The purposes of this study are to determine 1) If the use of Carac, followed by PDT treatment, of actinic keratoses leads to an enhanced clinical improvement as compared to PDT treatment alone; 2) If the cosmetic appearance of the skin during Carac is improved with PDT pre-treatment; 3) Evaluate histologic changes induced by combined Carac/PDT treatment as compared to Carac treatment alone and PDT treatment alone.;4) Evaluate safety of treatments in terms of potential for infection and scarring

Eligibility criteria: Inclusion Criteria:

* Males/females,, aged 40-70
* Must have 5 or more documented facial/anterior scalp actinic keratoses
* Read, understood, and signed informed consent form
* Willing and able to comply with all follow-up requirements

Exclusion Criteria:

* Previous treatment of facial keratoses with any modality of treatment within 3 months of study enrollment
* Contraindications to the use of either Carac and/or PDT treatment
* Exclusion of biopsy proven skin cancer in the area
* Active infections or dermatitis in the treatment area

Primary outcomes:
measure: Reduction of Actinic Keratoses
timeFrame: Outcomes are assessed at 3 months
Secondary outcomes:
measure: Photographic Improvement of Actinic Keratoses
timeFrame: Outcomes are assessed at 3 months
Other outcomes:
Locations:
Study officials:
References: